Stock MEGA-R MEGA LIFESCIENCES
Add to a list
To use this feature you must be a member
Log inSign up

Financials Mega Lifesciences Thailand S.E.

Equities

MEGA-R

TH4984010R19

Pharmaceuticals

End-of-day quote Thailand S.E.
Other stock markets
 03:30:00 02/07/2024 am IST 		5-day change 1st Jan Change
37.25 THB -1.97% Intraday chart for Mega Lifesciences -1.97% -7.45%
13/05 Mega Lifesciences Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
23/02 Transcript : Mega Lifesciences Public Company Limited, 2023 Earnings Call, Feb 23, 2024

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 22,669 31,169 44,029 40,760 35,093 32,477 - -
Enterprise Value (EV) 1 22,104 30,451 41,666 38,309 32,456 29,324 28,706 28,826
P/E ratio 19.8 x 22.3 x 22.6 x 18.2 x 17.6 x 12.8 x 12.3 x 11.6 x
Yield 2.77% 2.52% 2.1% 3.44% 4.1% 4.67% 4.99% 5.44%
Capitalization / Revenue 2.03 x 2.47 x 3.08 x 2.6 x 2.24 x 2.01 x 1.91 x 1.82 x
EV / Revenue 1.98 x 2.41 x 2.91 x 2.44 x 2.07 x 1.81 x 1.69 x 1.62 x
EV / EBITDA 13.7 x 15.6 x 17.2 x 13 x 10.2 x 8.98 x 8.43 x 7.96 x
EV / FCF 22.9 x 21.8 x 16.2 x 22.6 x 19.6 x 12.3 x 11.6 x 11.1 x
FCF Yield 4.37% 4.58% 6.18% 4.42% 5.09% 8.16% 8.61% 9.04%
Price to Book 3.67 x 4.48 x 5.5 x 4.64 x 3.77 x 3.18 x 2.86 x 2.78 x
Nbr of stocks (in thousands) 8,71,870 8,71,870 8,71,870 8,71,870 8,71,870 8,71,870 - -
Reference price 2 26.00 35.75 50.50 46.75 40.25 37.25 37.25 37.25
Announcement Date 24/02/20 22/02/21 23/02/22 25/02/23 22/02/24 - - -
1THB in Million2THB
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 11,179 12,643 14,301 15,686 15,681 16,179 17,023 17,847
EBITDA 1 1,613 1,951 2,426 2,953 3,190 3,265 3,407 3,620
EBIT 1 1,451 1,695 2,305 2,681 2,904 3,025 3,056 3,246
Operating Margin 12.98% 13.41% 16.12% 17.09% 18.52% 18.7% 17.95% 18.19%
Earnings before Tax (EBT) 1 1,299 1,623 2,277 2,595 2,262 2,950 3,104 3,324
Net income 1 1,139 1,393 1,947 2,242 1,993 2,527 2,608 2,793
Net margin 10.18% 11.02% 13.61% 14.29% 12.71% 15.62% 15.32% 15.65%
EPS 2 1.310 1.600 2.230 2.570 2.290 2.908 3.017 3.202
Free Cash Flow 1 966.6 1,395 2,575 1,692 1,652 2,392 2,472 2,606
FCF margin 8.65% 11.03% 18.01% 10.79% 10.53% 14.78% 14.52% 14.6%
FCF Conversion (EBITDA) 59.91% 71.49% 106.16% 57.3% 51.78% 73.27% 72.55% 71.98%
FCF Conversion (Net income) 84.9% 100.17% 132.29% 75.49% 82.9% 94.67% 94.75% 93.31%
Dividend per Share 2 0.7200 0.9000 1.060 1.610 1.650 1.740 1.859 2.026
Announcement Date 24/02/20 22/02/21 23/02/22 25/02/23 22/02/24 - - -
1THB in Million2THB
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1
Net sales 1 5,710 6,865 3,311 3,820 3,930 4,052 3,884 3,728 3,992 7,720 3,803 4,158 3,733
EBITDA 815.6 1,115 587.3 791.8 669.2 - 667.7 - - 1,525 - 874.3 -
EBIT 1 - - 553.3 724.9 590.2 769.5 599.6 616.1 786.5 1,385 718.1 801.1 218.7
Operating Margin - - 16.71% 18.98% 15.02% 18.99% 15.44% 16.52% 19.7% 17.94% 18.88% 19.27% 5.86%
Earnings before Tax (EBT) 1 706.8 993 547.7 716.6 631.9 778.5 467.6 526 571 - 633.1 531.6 548.5
Net income 1 623.3 837.8 496.4 614 569.5 658.3 399.8 453 530.9 983.9 535.5 473.2 477.6
Net margin 10.92% 12.2% 14.99% 16.07% 14.49% 16.24% 10.29% 12.15% 13.3% 12.74% 14.08% 11.38% 12.8%
EPS 2 0.7100 0.9600 0.5664 0.7000 0.6500 0.7600 0.4600 0.5200 0.6100 1.130 0.6100 0.5500 0.5500
Dividend per Share - - - - - - - - - - - - -
Announcement Date 14/08/20 16/08/21 23/02/22 13/05/22 11/08/22 14/11/22 25/02/23 12/05/23 11/08/23 11/08/23 13/11/23 22/02/24 14/05/24
1THB in Million2THB
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 565 718 2,363 2,451 2,636 3,153 3,772 3,652
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 967 1,395 2,575 1,692 1,652 2,392 2,472 2,606
ROE (net income / shareholders' equity) 19.1% 21.2% 26% 26.7% 22% 26.2% 24.7% 25.3%
ROA (Net income/ Total Assets) 11.3% 12.6% 15.7% 16.1% 13.9% 16.9% 16.5% 17.3%
Assets 1 10,070 11,061 12,414 13,959 14,381 14,951 15,850 16,142
Book Value Per Share 2 7.080 7.980 9.180 10.10 10.70 11.70 13.00 13.40
Cash Flow per Share 2 1.720 2.330 3.040 3.420 3.380 3.090 3.120 3.090
Capex 1 529 234 151 305 275 330 312 329
Capex / Sales 4.73% 1.85% 1.06% 1.94% 1.75% 2.04% 1.83% 1.84%
Announcement Date 24/02/20 22/02/21 23/02/22 25/02/23 22/02/24 - - -
1THB in Million2THB
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Mega Lifesciences

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
37.25 THB
Average target price
48.88 THB
Spread / Average Target
+31.21%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.55% 816B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.14% 634B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.83% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.15% 323B
ABBVIE INC. Stock AbbVie Inc.
+7.09% 293B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.58% 238B
ROCHE HOLDING AG Stock Roche Holding AG
+1.68% 222B
NOVARTIS AG Stock Novartis AG
+13.73% 218B
AMGEN INC. Stock Amgen Inc.
+7.87% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MEGA Stock
  4. MEGA-R Stock
  5. Financials Mega Lifesciences